DIPO: Dairy Intervention in People With Obesity
Study Details
Study Description
Brief Summary
Obesity is associated with increased morbidity and mortality, but weight reduction is difficult to achieve. In this randomized controlled trial we will include 120 obese subjects.
Subjects will be allocated to one of the 3 diet types (minus 500 kcal / d):
-
Yoghurt diet: 500 g low-fat yogurt / d, about 1000-1100 mg calcium / d,
-
Milk product diet: 500 g of low-fat milk or buttermilk / d, about 1000-1100 mg calcium / d
-
Standard diet: 500 g soy yogurt / d, about 500 mg calcium / d Primary endpoint is the change in fat mass (baseline vs. 12 weeks), secondary endpoints are metabolic and endocrine parameters, gut microbiome, quality of life, hunger and satiety.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: yogurt diet yogurt-diet (-500 kcal/day, 500 g yogurt, high calcium) |
Dietary Supplement: yogurt diet
500 g yogurt/day
|
| Active Comparator: dairy diet dairy diet: -500 kcal/day, high calcium, 500 g non-yogurt dairy products |
Dietary Supplement: dairy diet
500 g non-yogurt dairy products
|
| Active Comparator: standard diet standard diet: -500 kcal/day, low calcium, 500 g soya-yogurt |
Dietary Supplement: standard diet
500 g soya-yogurt
|
Outcome Measures
Primary Outcome Measures
- fat mass [12 weeks]
Changes in body fat mass assessed via dual-energy X-ray absorptiometry (DXA) (baseline vs. 12 weeks).
Secondary Outcome Measures
- Body weight [12 weeks]
body weight [kg]
- BMI [12 weeks]
BMI [kg/m²]
- waist circumference [12 weeks]
waist circumference [cm]
- hip circumference [12 weeks]
hip circumference [cm]
- Systolic blood pressure [12 weeks]
systolic blood pressure [mm Hg]
- Diastolic blood pressure [12 weeks]
diastolic blood pressure [mm Hg]
- Body composition-lean mass [12 weeks]
lean mass [kg]
- Body composition-total body fat [12 weeks]
total body fat ([%]
- Body composition-gynoid fat mass [12 weeks]
gynoid fat mass [kg]
- Body composition-android fat mass [12 weeks]
android fat mass [kg]
- AUCglucose [12 weeks]
Metabolic response during an oral glucose tolerance test (oGTT) as defined by AUCglucose
- AUCinsulin [12 weeks]
Metabolic response during an oral glucose tolerance test (oGTT) as defined by AUCinsulin
- HOMA-IR [12 weeks]
Insulin resistance assessed by homeostatic model assessment-insulin resistance (HOMA-IR)
- HOMA-beta [12 weeks]
insulin sensitivity assessed by HOMA-beta
- MATSUDA [12 weeks]
insulin sensitivity assessed by MATSUDA-index
- QUICKI [12 weeks]
insulin sensitivity assessed by Quantitative Insulin-sensitivity Check Index (QUICKI)
- Total cholesterol [12 weeks]
Total cholesterol [mg/dl]
- LDL cholesterol [12 weeks]
LDL cholesterol [mg/dl]
- HDL cholesterol [12 weeks]
HDL cholesterol [mg/dl]
- Triglycerides [12 weeks]
Triglycerides [mg/dl]
- HbA1c [12 weeks]
HbA1c [mmol/mol]
- Total testosterone [12 weeks]
Total testosterone [nmol/l]
- Free testosterone [12 weeks]
Free testosterone [nmol/l]
- Free androgen index [12 weeks]
FAI (Free androgen index)
- androstenedione [12 weeks]
androstenedione [nmol/l]
- DHEAS [12 weeks]
dehydroepiandrosterone sulfate (DHEAS) [µmol/L]
- stool microbiome [12 weeks]
Composition of the stool microbiome Microbiome analysis will be performed through the following steps: patient collection and provision of a stool specimen, DNA isolation from the specimen, PCR reaction to amplify the selected region of the 16S rRNA gene (only present in bacteria), sequencing of the amplicons using next-generation sequencing technology, bioinformatics processing and analysis of the data using suitable software.
- Satiety [12 weeks]
assessed via visual analogue scale [VAS]: "Satiety", minimum score 0, maximum score 10, higher scores mean a worse outcome.
- Food craving [12 weeks]
assessed via visual analogue scale [VAS]: "Food craving", minimum score 0, maximum score 10, higher scores mean a worse outcome.
- Quality of life during weight reduction [12 weeks]
Quality of life assessed via visual analogue scale [VAS]: "How is your quality of life during weight reduction?", minimum score 0, maximum score 10, higher scores mean a better outcome.
- Compliance [12 weeks]
assessed via visual analogue scale [VAS]: "Compliance", minimum score 0, maximum score 10, higher scores mean a better outcome.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
BMI ≥30 kg/m²
-
Age of ≥18 and <60 years
-
Written informed consent before study entry
-
Willingness to introduce a dietary change to lose weight
Exclusion Criteria:
-
Serum calcium ≥2.7 mmol/l
-
Dislike or intolerance of dairy products, reporting adverse responses or allergy to dairy products
-
Pregnancy or lactating women
-
Having given birth in the last year or planning a pregnancy in the next 6 months
-
Menopause (as defined by FSH levels ≥30 IU/l)
-
Disorders associated with androgen excess and/or menstrual irregularities except PCOS (overt thyroid dysfunction, hyperprolactinemia, adrenal hyperplasia, androgen secreting tumors)
-
Malabsorption syndrome
-
Intake of medication influencing metabolic or endocrine parameters (insulin sensitizers, oral contraceptives, …), obesity pharmacotherapeutic agents, or calcium supplements in the last 3 months before study entry
-
Regular intake of calcium supplements in the last 3 months before study entry
-
Lifestyle changes (changes in physical activity) or weight reduction (≥10% of body weight) in the last 3 months before study entry
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medical University of Graz, Department of Internal Medicine, Division of Endocrinology and Metabolism | Graz | Austria | 8036 |
Sponsors and Collaborators
- Medical University of Graz
Investigators
- Principal Investigator: Elisabeth Lerchbaum, MD, Medical University of Graz
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DIPO 1.0